Conclusions
In this analysis of 17,524 OHT recipients, we demonstrate that the
institutional utilization of induction therapy is highly variable across
transplant centers and not necessarily attributable to differences in
patients’ baseline rejection risk. Furthermore, other unmeasured
center-level factors appear to contribute to differences in 1-year
rejection rates to a higher degree than induction therapy use. The
identification of such factors and efforts to better standardize
induction therapy use in OHT appear prudent.